Hypophosphatasia: an overview of the disease and its treatment

Osteoporosis International

Volumn 26, Issue 12, 2015, Pages 2743-2757

  Bianchi, M L ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Alkaline phosphatase; Bone; Fractures; Hypomineralization; Hypophosphatasia; Teeth

Indexed keywords

ALKALINE PHOSPHATASE; ASFOTASE ALFA; BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; TISSUE NON SPECIFIC ALKALINE PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT DISEASE; BONE MARROW TRANSPLANTATION; BONE MINERALIZATION; CHILDHOOD DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENZYME REPLACEMENT; FRACTURE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HYPOPHOSPHATASIA; INFLAMMATION; INJECTION SITE REACTION; KIDNEY DISEASE; LABORATORY TEST; LOSS OF FUNCTION MUTATION; MENTAL DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROLOGIC DISEASE; NUTRITION; OSTEOPOROSIS; PATHOGENESIS; PERINATAL MORBIDITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRENATAL DIAGNOSIS; PRENATAL DISORDER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIOGRAPHY; REVIEW; SCOLIOSIS; TOOTH DISEASE; DISEASE MANAGEMENT; GENETICS;

DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; HYPOPHOSPHATASIA;

EID: 84948712705     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3272-1     Document Type: Review

References (125)

1. Rathbun JC (1948) Hypophosphatasia; a new developmental anomaly. Am J Dis Child 75:822–831
2. Caswell AM, Whyte MP, Russell RG (1991) Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit Rev Clin Lab Sci 28:175–232
3. Cole DEC (2008) Hypophosphatasia update: recent advances in diagnosis and treatment. Clin Genet 73:232–235
4. Hofmann C, Girschick HJ, Mentrup B, Graser S, Seefried L, Liese J, Jakob F (2013) Clinical aspects of hypophosphatasia: an update. Clinic Rev Bone Miner Metab 11:60–70
5. Mornet E (2007) Hypophosphatasia. Orphanet J Rare Dis 2:40. doi:10.1186/1750-1172-2-40
6. Mornet E (2008) Hypophosphatasia. Best Pract Res Clin Rheumatol 22:113–127
7. Rockman-Greenberg C (2013) Hypophosphatasia. Pediatr Endocrinol Rev 10(Suppl 2):380–388
8. Hoshi K, Amizuka N, Oda K, Ikehara Y, Ozawa H (1997) Immunolocalization of tissue non-specific alkaline phosphatase in mice. Histochem Cell Biol 107:183–191
9. Whyte MP (2010) Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann NY Acad Sci 1192:190–200
10. Fonta C, Negyessy L, Renaud L, Barone P (2005) Postnatal development of alkaline phosphatase activity correlates with the maturation of neurotransmission in the cerebral cortex. J Comp Neurol 486:179–196
11. Miao D, Scutt A (2002) Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage. J Histochem Cytochem 50:333–340
12. Whyte MP, Mahuren JD, Vrabel LA, Coburn SP (1985) Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest 76:752–756
13. Narisawa S, Wennberg C, Millan JL (2001) Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. J Pathol 193:125–133
14. Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Bürgi S, Sergi C, Ryan L, Ericson KL, Whyte MP, Högler W (2007) Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T.C, p.M226T; c.1112C.T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone 40:1655–1661
15. Nunes ML, Mugnol F, Bica I, Fiori RM (2002) Pyridoxine-dependent seizures associated with hypophosphatasia in a newborn. J Child Neurol 17:222–224
16. Yamamoto H, Sasamoto Y, Miyamoto Y, Murakami H, Kamiyama N (2004) A successful treatment with pyridoxal phosphate for West syndrome in hypophosphatasia. Pediatr Neurol 30:216–218
17. Kermer V, Ritter M, Albuquerque B, Leib C, Stanke M, Zimmermann H (2010) Knockdown of tissue nonspecific alkaline phosphatase impairs neural stem cell proliferation and differentiation. Neurosci Lett 485:208–211
18. Buchet R, Millán JL, Magne D (2013) Multisystemic functions of alkaline phosphatase. In: José Luis Millán (ed.). Phosphatase modulators. Methods in molecular biology. Springer Science + Business Media - Humana Press, New York, pp. 27-51. doi: 10.1007/978-1-62703-562-0_3
19. Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H (1988) Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 263:12002–12010
20. Smith M, Weiss MJ, Griffin CA, Murray JC, Buetow KH, Emanuel BS, Henthorn PS, Harris H (1988) Regional assignment of the gene for human liver/bone/kidney alkaline phosphatase to chromosome 1p36.1-p34. Genomics 2:139–143
21. Silvent J, Gasse B, Mornet E, Sire JY (2014) Molecular evolution of the tissue-nonspecific alkaline phosphatase allows prediction and validation of missense mutations responsible for hypophosphatasia. J Biol Chem 289:24168–24179
22. Griffin CA, Smith M, Henthorn PS, Harris H, Weiss MJ, Raducha M, Emanuel BS (1987) Human placental and intestinal alkaline phosphatase genes map to 2q34eq37. Am J Hum Genet 41:1025–1034
23. Mornet E, Beck C, Bloch-Zupan A, Girschick H, Le Merrer M (2011) Clinical utility gene card for: hypophosphatasia. Eur J Hum Genet 19. doi:10.1038/ejhg.2010.170
24. Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M (2014) Clinical utility gene card for: hypophosphatasia—update 2013. Eur J Hum Genet 22. doi: 10.1038/ejhg.2013.177
25. Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51
26. Hu JC, Plaetke R, Mornet E, Zhang C, Sun X, Thomas HF, Simmer JP (2000) Characterization of a family with dominant hypophosphatasia. Eur J Oral Sci 108:189–194
27. Lia-Baldini AS, Brun-Heath I, Carrion C, Simon-Bouy B, Serre JL, Nunes ME, Mornet E (2008) A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein. Hum Genet 123:429–432
28. Lia-Baldini AS, Muller F, Taillandier A, Gibrat JF, Mouchard M, Robin B, Simon-Bouy B, Serre JL, Aylsworth AS, Bieth E, Delanote S, Freisinger P, Hu JC, Krohn HP, Nunes ME, Mornet E (2001) A molecular approach to dominance in hypophosphatasia. Hum Genet 109:99–108
29. Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet 22:1160–1164
30. Goseki-Sone M, Sogabe N, Fukushi-Irie M, Mizoi L, Orimo H, Suzuki T, Nakamura H, Orimo H, Hosoi T (2005) Functional analysis of the single nucleotide polymorphism (787T>C) in the tissue-nonspecific alkaline phosphatase gene associated with BMD. J Bone Miner Res 20:773–782
31. Nielson CM, Zmuda JM, Carlos AS, Wagoner WJ, Larson EA, Orwoll ES, Klein RF (2012) Rare coding variants in ALPL are associated with low serum alkaline phosphatase and low bone mineral density. J Bone Miner Res 27:93–103
32. Fraser D (1957) Hypophosphatasia. Am J Med 22:730–746
33. Orton NC, Innes AM, Chudley AE, Bech-Hansen NT (2008) Unique disease heritage of the Dutch-German Mennonite population. Am J Med Genet A 146A:1072–1087
34. Greenberg CR, Evans JA, McKendry-Smith S, Redekopp S, Haworth JC, Mulivor R, Chodirker BN (1990) Infantile hypophosphatasia: localization within chromosome region 1p36.1-34 and prenatal diagnosis using linked DNA markers. Am J Hum Genet 46:286–292
35. Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B (2011) A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet 75:439–445
36. Watanabe A, Karasugi T, Sawai H, Naing BT, Ikegawa S, Orimo H, Shimada T (2011) Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. J Hum Genet 56:166–168
37. Whyte MP, Essmyer K, Geimer M, Mumm S (2006) Homozygosity for TNSALP mutation 1348c>T (Arg433Cys) causes infantile hypophosphatasia manifesting transient disease correction and variably lethal outcome in a kindred of black ancestry. J Pediatr 148:753–758
38. Millán JL (2013) The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int 93:299–306
39. Glimcher MJ (2006) Bone: nature of the calcium phosphate crystals and cellular, structural, and physical chemical mechanisms in their formation. Rev Mineral Geochem 64:223–282
40. Anderson HC (1969) Vesicles associated with calcification in the matrix of epiphyseal cartilage. J Cell Biol 41:59–72
41. Anderson HC (1995) Molecular biology of matrix vesicles. Clin Orthop Relat Res 314:266–280
42. Golub EE (2009) Role of matrix vesicles in biomineralization. Biochim Biophys Acta 1790:1592–1598
43. Schinke T, McKee MD, Karsenty G (1999) Extracellular matrix calcification: where is the action? Nat Genet 21:150–151
44. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 99:9445–9449
45. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164:1199–1209
46. Anderson HC, Sipe JB, Hessle L, Dhanyamraju R, Atti E, Camacho NP, Millán JL (2004) Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 164:841–847
47. Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 77:4–12
48. Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, Millán JL (2000) Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 15:1879–1888
49. Atar M, Körperich EJ (2010) Systemic disorders and their influence on the development of dental hard tissues: a literature review. J Dent 38:296–306
50. van den Bos T, Handoko G, Niehof A, Ryan LM, Coburn SP, Whyte MP, Beertsen W (2005) Cementum and dentin in hypophosphatasia. J Dent Res 84:1021–1025
51. Olsson A, Matsson L, Blomquist HK, Larsson A, Sjodin B (1996) Hypophosphatasia affecting the permanent dentition. J Oral Pathol Med 25:343–347
52. Beumer J III, Trowbridge HO, Silverman S Jr, Eisenberg E (1973) Childhood hypophosphatasia and the premature loss of teeth. A clinical and laboratory study of seven cases. Oral Surg Oral Med Oral Pathol 35:631–640
53. Brittain JM, Oldenburg TR, Burkes EJ Jr (1976) Odontohypophosphatasia: report of two cases. ASDC J Dent Child 43:106–111
54. Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, Coburn SP, Wagy S, Griffin DM, Ericson KL, Mumm S (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229–239
55. Fallon MD, Teitelbaum SL, Weinstein RS, Goldfischer S, Brown DM, Whyte MP (1984) Hypophosphatasia: clinicopathologic comparison of the infantile, childhood, and adult forms. Medicine (Baltimore) 63:12–24
56. Whyte MP (2001) Hypophosphatasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 5313–5329
57. Hofmann C, Liese J, Schwarz T, Kunzmann S, Wirbelauer J, Nowak J, Hamann J, Girschick H, Graser S, Dietz K, Zeck S, Jakob F, Mentrup B (2013) Compound heterozygosity of two functional null mutations in the ALPL gene associated with deleterious neurological outcome in an infant with hypophosphatasia. Bone 55:150–157
58. Balasubramaniam S, Bowling F, Carpenter K, Earl J, Chaitow J, Pitt J, Mornet E, Sillence D, Ellaway C (2010) Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5'-phosphate availability. J Inherit Metab Dis 33(Suppl 3):S25–33
59. Watanabe A, Yamamasu S, Shinagawa T, Suzuki Y, Miyake H, Takeshita T, Orimo H, Shimada T (2007) Prenatal genetic diagnosis of severe perinatal (lethal) hypophosphatasia. J Nippon Med Sch 74:65–69
60. Moore CA, Curry CJ, Henthorn PS, Smith JA, Smith JC, O'Lague P, Coburn SP, Weaver DD, Whyte MP (1999) Mild autosomal dominant hypophosphatasia: in utero presentation in two families. Am J Med Genet 86:410–415
61. Pauli RM, Modaff P, Sipes SL, Whyte MP (1999) Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: bent but not broken. Am J Med Genet 86:434–438
62. Matsushita M, Kitoh H, Michigami T, Tachikawa K, Ishiguro N (2014) Benign prenatal hypophosphatasia: a treatable disease not to be missed. Pediatr Radiol 44:340–343
63. Müller HL, Yamazaki M, Michigami T, Kageyama T, Schönau E, Schneider P, Ozono K (2000) Asp361Val mutant of alkaline phosphatase found in patients with dominantly inherited hypophosphatasia inhibits the activity of the wild-type enzyme. J Clin Endocrinol Metab 85:743–747
64. Wenkert D, McAlister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 26:2389–2398
65. Silva I, Castelão W, Mateus M, Branco JC (2012) Childhood hypophosphatasia with myopathy: clinical report with recent update. Acta Reumatol Port 37:92–96
66. Arun R, Khazim R, Webb JK, Burn J (2005) Scoliosis in association with infantile hypophosphatasia. A case study in two siblings. Spine 30:E471–E476
67. Moulin P, Vaysse F, Bieth E, Mornet E, Gennero I, Dalicieux-Laurencin S, Baunin C, Tauber MT, De Gauzy JS, Salles JP (2009) Hypophosphatasia may lead to bone fragility: don't miss it. Eur J Pediatr 168:783–788
68. Berkseth KE, Tebben PJ, Drake MT, Hefferan TE, Jewison DE, Wermers RA (2013) Clinical spectrum of hypophosphatasia diagnosed in adults. Bone 54:21–27
69. Khandwala HM, Mumm S, Whyte MP (2006) Low serum alkaline phosphatase activity and pathologic fracture: case report and brief review of hypophosphatasia diagnosed in adulthood. Endocr Pract 12:676–681
70. Coe JD, Murphy WA, Whyte MP (1986) Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am 68:981–990
71. Yavuz U, Sökücü S, Demir B, Akpjnar E, Lapçin O, Atjcj Y, Kabukçuoglu Y (2013) An unusual stress fracture in an archer with hypophosphatasia. Case Rep Orthop 2013:350236. doi:10.1155/2013/350236
72. Barvencik F, Beil FT, Gebauer M, Busse B, Koehne T, Seitz S, Zustin J, Pogoda P, Schinke T, Amling M (2011) Skeletal mineralization defects in adult hypophosphatasia—a clinical and histological analysis. Osteoporos Int 22:2667–2675
73. Wüster C, Ziegler R (1992) Reduced bone mineral density and low parathyroid hormone levels in patients with the adult form of hypophosphatasia. Clin Investig 70:560–565
74. Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP (2012) "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 27:987–994
75. Whyte MP (2009) Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res 24:1132–1134
76. Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ (2009) How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 29:229–238
77. Guañabens N, Mumm S, Möller I, González-Roca E, Peris P, Demertzis JL, Whyte MP (2014) Calcific periarthritis as the only clinical manifestation of hypophosphatasia in middle-aged sisters. J Bone Miner Res 29:929–934
78. Chapple IL (1993) Hypophosphatasia: dental aspects and mode of inheritance. J Clin Periodontol 20:615–622
79. Herasse M, Spentchian M, Taillandier A, Keppler-Noreuil K, Fliorito AN, Bergoffen J, Wallerstein R, Muti C, Simon-Bouy B, Mornet E (2003) Molecular study of three cases of odontohypophosphatasia resulting from heterozygosity for mutations in the tissue non-specific alkaline phosphatase gene. J Med Gen 40:605–609
80. Royce PM, Blumberg A, Zurbrügg RP, Zimmermann A, Colombo JP, Steinmann B (1988) Lethal osteogenesis imperfecta: abnormal collagen metabolism and biochemical characteristics of hypophosphatasia. Eur J Pediatr 147:626–631
81. Unger S, Mornet E, Mundlos S, Blaser S, Cole DE (2002) Severe cleidocranial dysplasia can mimic hypophosphatasia. Eur J Pediatr 161:623–626
82. Wyckoff MH, El-Turk C, Laptook A, Timmons C, Gannon FH, Zhang X, Mumm S, Whyte MP (2005) Neonatal lethal osteochondrodysplasia with low serum levels of alkaline phosphatase and osteocalcin. J Clin Endocrinol Metab 90:1233–1240
83. Taillandier A, Sallinen S-L, Brun-Heath I, De Mazancourt P, Serre J-L, Mornet E (2005) Childhood hypophosphatasia due to a de novo missense mutation in the tissue-nonspecific alkaline phosphatase gene. J Clin Endocrinol Metab 90:2436–2439
84. Simon-Bouy B, Taillandier A, Fauvert D, Brun-Heath I, Serre JL, Armengod CG, Bialer MG, Mathieu M, Cousin J, Chitayat D, Liebelt J, Feldman B, Gérard-Blanluet M, Körtge-Jung S, King C, Laivuori H, Le Merrer M, Mehta S, Jern C, Sharif S, Prieur F, Gillessen-Kaesbach G, Zankl A, Mornet E (2008) Hypophosphatasia: molecular testing of 19 prenatal cases and discussion about genetic counseling. Prenat Diagn 28:993–998
85. Gwinn JL, Lee FA, Joshi NC, Dessai MP (1971) Radiological case of the month. Hypophosphatasia in the newborn. Am J Dis Child 122:151–152
86. Kaplan SB, Kemp SS, Oh KS (1991) Radiographic manifestations of congenital anomalies of the skull. Radiol Clin North Am 29:195–218
87. Glass RB, Fernbach SK, Norton KI, Choi PS, Naidich TP (2004) The infant skull: a vault of information. Radiographics 24:507–522
88. Kozlowski K, Sutcliffe J, Barylak A, Harrington G, Kemperdick H, Nolte K, Rheinwein H, Thomas PS, Uniecke W (1976) Hypophosphatasia. Review of 24 cases. Pediatr Radiol 15:103–117
89. Girschick HJ, Mornet E, Beer M, Warmuth-Metz M, Schneider P (2007) Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy. BMC Pediatr 7:3. doi:10.1186/1471-2431-7-3
90. Whyte MP, Wenkert D, McAlister WH, Mughal MZ, Freemont AJ, Whitehouse R, Baildam EM, Coburn SP, Ryan LM, Mumm S (2009) Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. J Bone Miner Res 24:1493–1505
91. Beck C, Morbach H, Wirth C, Beer M, Girschick HJ (2011) Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int 31:1315–1320
92. Sumner TE, Volberg FM, Karstaedt N, Ward CF, Lorentz WB (1984) Hypophosphatasia and nephrocalcinosis demonstrated by ultrasound and CT. Clin Nephrol 22:317–319
93. Girschick HJ, Haubitz I, Hiort O, Schneider P (2007) Long-term follow-up of bone mineral density in childhood hypophosphatasia. Joint Bone Spine 74:263–269
94. Anderson HC, Hsu HH, Morris DC, Fedde KN, Whyte MP (1997) Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals. Am J Pathol 151:1555–1561
95. Jakob F, Hofmann C, Seefried L (2012) Hypophosphatasia—upcoming treatments. Bull Group Int Rech Sci Stomatol Odontol 51:42
96. Wenkert D, Podgornik MN, Coburn SP, Ryan LM, Mumm S, Whyte MP (2002) Dietary phosphate restriction therapy for hypophosphatasia: preliminary observations. J Bone Miner Res 17(suppl 1):S384
97. Mornet E, Nunes ME (2011) Hypophosphatasia. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds). GeneReviews® [Internet] 1993-2014, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1150/
98. Girschick HJ, Schneider P, Haubitz I, Hiort O, Collmann H, Beer M, Shin YS, Seyberth HW (2006) Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia. Orphanet J Rare Dis 1:24. doi:10.1186/1750-1172-1-24
99. Whyte MP, Mumm S, Deal C (2007) Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 92:1203–1208
100. Camacho PM, Painter S, Kadanoff R (2008) Treatment of adult hypophosphatasia with teriparatide. Endocr Pract 14:204–208
101. Schalin-Jäntti C, Mornet E, Lamminen A, Välimäki MJ (2010) Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia. J Clin Endocrinol Metab 95:5174–5149
102. Gagnon C, Sims NA, Mumm S, McAuley SA, Jung C, Poulton IJ, Ng KW, Ebeling PR (2010) Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab 95:1007–1012
103. Laroche M (2012) Failure of teriparatide in treatment of bone complications of adult hypophosphatasia. Calcif Tissue Int 90:250
104. Doshi KB, Hamrahian AH, Licata AA (2009) Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: a case report. Clin Cases Miner Bone Metab 6:266–269
105. Deeb AA, Bruce SN, Morris AAM, Cheetham TD (2000) Infantile hypophosphatasia: disappointing results of treatment. Acta Paedriatr 89:730–743
106. Millán JL, Plotkin H (2012) Hypophosphatasia—pathophysiology and treatment. Actual Osteol 8:164–182
107. Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H (2009) Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst 25:217–223
108. Whyte MP, Kurtzberg J, McAlister WH, Mumm S, Podgornik MN, Coburn SP, Ryan LM, Miller CR, Gottesman GS, Smith AK, Douville J, Waters-Pick B, Armstrong RD, Martin PL (2003) Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 18:624–636
109. Cahill RA, Wenkert D, Perlman SA, Steele A, Coburn SP, McAlister WH, Mumm S, Whyte MP (2007) Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. J Clin Endocrinol Metab 92:2923–2930
110. Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H (2009) New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J Pediatr 154:924–930
111. Taketani T, Kanai R, Abe M, Mishima S, Tadokoro M, Katsube Y, Yuba S, Ogushi H, Fukuda S, Yamaguchi S (2013) Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia. Pediatr Int 55:e52–5. doi:10.1111/ped.12012
112. Taketani T, Oyama C, Mihara A, Tanabe Y, Abe M, Hirade T, Yamamoto S, Bo R, Kanai R, Tadenuma T, Michibata Y, Yamamoto S, Hattori M, Katsube Y, Ohnishi H, Sasao M, Oda Y, Hattori K, Yuba S, Ohgushi H, Yamaguchi S (2014) Ex vivo expanded allogeneic mesenchymal stem cells with bone marrow transplantation improved osteogenesis in infants with severe hypophosphatasia. Cell Transplant
113. Whyte MP, Valdes R Jr, Ryan LM, McAlister WH (1982) Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr 101:379–386
114. Weninger M, Stinson RA, Plenk H Jr, Böck P, Pollak A (1989) Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand Suppl 360:154–160
115. Whyte MP, Habib D, Coburn SP, Tecklenburg F, Ryan L, Fedde KN, Stinson RA (1992) Failure of hyperphosphatasemia by intravenous infusion of purified placental alkaline phosphatase (ALP) to correct severe hypophosphatasia: evidence against a role for circulating ALP in skeletal mineralization. J Bone Miner Res 7(Suppl1):S155
116. Millán JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Pleshko Camacho N, McKee MD, Crine P, Whyte MP (2008) Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 23:777–787
117. McKee MD, Nakano Y, Masica DL, Gray JJ, Lemire I, Heft R, Whyte MP, Crine P, Millán JL (2011) Enzyme replacement prevents dental defects in a mouse model of hypophosphatasia. J Dent Res J Dent Res 90:470–476
118. Yadav MC, Lemire I, Leonard P, Boileau G, Blond L, Beliveau M, Cory E, Sah RL, Whyte MP, Crine P, Millán JL (2011) Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone 49:250–256
119. Foster BL, Nagatomo KJ, Tso HW, Tran AB, Nociti FH Jr, Narisawa S, Yadav MC, McKee MD, Millán JI, Somerman MJ (2013) Tooth root dentin mineralization defects in a mouse model of hypophosphatasia. J Bone Miner Res 28:271–82
120. Rodriguez E, Bober MB, Davey L, Zamora A, Li Puma AB, Chidekel A, Shaffer TH (2012) Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy. Pediatr Pulmonol 47:917–922
121. Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millán JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913
122. Whyte MP, Simmons JH, Bishop N, Lutz RE, Vallée M, Melian A, Odrljin T; for the Study 003-08 Investigators (2014) Asfotase alfa: sustained efficacy and tolerability in infants and young children with life-threatening hypophosphatasia. Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, Vancouver, BC, Canada, May 3-6, 2014
123. Madson KL, Rockman-Greenberg C, Melian A, Moseley S, Odrljin T, Whyte MP; for the Study 008-10 Investigators (2014) Asfotase alfa: long-term safety and efficacy in children with hypophosphatasia. Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting, Vancouver, BC, Canada, May 3-6, 2014
124. Rockman-Greenberg C, Vockley J, Harmatz P, Vallée M, Bedrosian CL, Hofmann C, Liese J (2014) Asfotase alfa improves skeletal mineralization and respiratory function in infants and young children with hypophosphatasia: results from up to 12 months’ treatment. American College of Medical Genetics & Genomics Annual Meeting, Nashville, TN, USA, March 25-29, 2014
125. Kishnani PS, Rockman-Greenberg C, Whyte MP, Weber T, Mhanni A, Madson K, Reeves A, Mack K, Plotkin H, Kreher N, Landy H (2012) Hypophosphatasia: enzyme replacement therapy (Asfotase alfa) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults. American College of Medical Genetics and Genomics Annual Meeting, Charlotte, NC, USA, March 27-31, 2012